This study H0P-MC-BP05 (NCT0 5630196) is a sub-study of Master Protocol H0P-MC-
CPMP ([STUDY_ID_REMOVED]) 
Protocol H0P-MC-BP05 (a) 
Randomized, Placebo-Co ntrolled, Phase 2 C linical Trial to Evaluate LY3857210 for 
the Treatment of Chronic Low Back Pain 
[STUDY_ID_REMOVED] 
Approval Date: 13-Oct-2022 
CONFIDENTIAL  Protocol number H0P-MC-BP05  (a) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_51937]3857210 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidenti al information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not b e reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Master Protocol Title:  A Master Protocol for Randomized, Placebo -Controlled, Phase 2 
Clinical Trials of Multiple Interventions for the Treatme nt of Chronic Pain  
Master Protocol Number: H0P-MC-CPMP  
ISA Title:  Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY 3857210  for 
the Treatment of Chronic Low Back  Pain 
Brief Title: Phase 2 Clinical Trial to Evaluate LY3857210 for the Trea tment of Chronic Low 
Back Pain  
ISA Number: H0P-MC-BP05  
Amendment Number:  a 
Compound : LY3857210  
Study Phase: 2 
Acronym : BP05   
Sponsor Name: [CONTACT_11028]: Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number s: 
LY3857210 IND: 156411  
Master Protocol IND: 144915  
Approval Date: Protocol  H0P-MC-BP05 Amendment (a) Electronically Signed and Approved 
by [CONTACT_81098].   
Document  ID: VV-CLIN -[ADDRESS_580841] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580842] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
3 Protocol Amendment Summary of Changes Table 
DOCUMENT HISTORY 
Document Date
Original Protoco l 21-Sep-202 2
Amendment a  
Overall Rationale for the Amendment: 
This amendment adds additional physical examinations and exclusion criteria to address 
regulatory feedback. 
Section # and 
Name [CONTACT_23688] 
1.3. Schedule 
of Activities Added Physical examinations  at Visits 5 and 7.   
Added note, “Complete physical examination, 
including targeted physical examination 
specified below, should be performed at V3 and V801 or ED. Targeted examinations for skin, gastrointestinal tract, mammary gland in males, and lymph nodes should also be performed at V5 and V7.” Per regulatory feedback. 
5.2. Exclusion Criteria Modified criterion [ 2085], “have completed 
participated in…”. Clarification. 
Per regulato ry feedback. 
8.2.1. Physical Examinations Added, “Complete physical examination, including targeted examination specified below, should be performed at V3 and Visit [ADDRESS_580843], mammary gland in males, and lymph nodes will also be performed at Visits V5 and V7 as described in the SoA. Any clinically signifi cant abnormal physical 
examination findings will be reported as AEs.” Per regulatory feedback. 
Removed, “…to physical examinations described in the Master Pr 
otocol CPMP…” Editorial. 
Approved on [ADDRESS_580844] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
4 Table of Contents 
1. Protocol Summary ..........................................................................................................7  
1.1.  Synopsis ...................................................................................................................... ......7 
1.2.  Schema ........................................................................................................................ ......9 
1.3.  Schedule of Activities (SoA) ..........................................................................................10  
2. Introduction ...................................................................................................................14  
2.1.  Study Rationale ...............................................................................................................14  
2.2.  Background .................................................................................................................... .14 
2.3.  Benefit/Risk Assessment ................................................................................................14  
2.3.1. Risk Assessment .............................................................................................................14  
2.3.2. Benefit Assessment .........................................................................................................15  
2.3.3. Overall Benefit Risk Conclusion ....................................................................................15  
3. Objectives, Endpoints, and Estimands .......................................................................16  
4. Study Design ..................................................................................................................17  
4.1.  Overall Design ................................................................................................................17  
4.2.  Scientific Rationale for Study Design ............................................................................17  
4.3.  Justification for Dose ......................................................................................................18  
4.4.  End of Study Definition ..................................................................................................18  
5. Study Population ...........................................................................................................19  
5.1.  Inclusion Criteria ............................................................................................................19  
5.2.  Exclusion Criteria ...........................................................................................................19  
5.3.  Lifestyle Considerations .................................................................................................20  
5.3.1. Substance Use ................................................................................................................. 20 
5.4.  Screen Failures ................................................................................................................20  
5.5.  Criteria for Temporarily Delaying Enrollment, Randomization, 
or Administration of Study In tervention of a Participant ...............................................20  
6. Study Intervention(s) and Concomitant Therapy ......................................................21  
6.1.  Study Intervention(s)  Administered ................................................................................21  
6.2.  Preparation, Handling, Storag e, and Accountability ......................................................21  
6.3.  Measures to Minimize Bias: Randomization and Blinding ............................................21  
6.3.1. Stratification ................................................................................................................ ....21 
6.4.  Study Intervention Compliance ......................................................................................21  
6.5.  Dose Modification ..........................................................................................................21  
6.6.  Continued Access to Study Interv ention after the End of the 
Study ......................................................................................................................... ......21 
6.7.  Treatment of Overdose ...................................................................................................22  
6.8.  Concomitant Therapy .....................................................................................................22  
6.8.1. Permitted Medications ....................................................................................................22  
6.8.2. Prohibited Medications ...................................................................................................22  
7. Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal........................................................................................[ADDRESS_580845] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
5 7.1.2. Hypersensitivity .............................................................................................................. 24 
7.2.  Participant Discontinuation/ Withdrawal from the Study ................................................[ADDRESS_580846] .................................................................................27  
8.4.  Pharmacokinetics ............................................................................................................28  
8.5.  Pharmacodynamics .........................................................................................................28  
8.6.  Genetics ...................................................................................................................... ....28 
.................................................................................................................... ..28 
.........................................................................................28  
 ....................................................28  
9. Statistical Considerations .............................................................................................29  
9.1.  Statistical Hypotheses .....................................................................................................29  
9.2.  Analyses Sets ..................................................................................................................29  
9.3.  Statistical Analyses .........................................................................................................2 9 
9.3.1. General Considerations ...................................................................................................29  
9.3.2. Tertiary Analysis .............................................................................................................29  
9.3.3. Safety Analyses ...............................................................................................................30  
9.3.4. Exploratory Pharmaco kinetic Analyses ..........................................................................30  
9.4.  Interim Analysis ..............................................................................................................30  
9.5.  Sample Size Determination ............................................................................................30  
10. Supporting Documentation and Operational Considerations ..................................31  
10.1. Appendix 1: Regulatory, Et hical, and Study Oversight 
Considerations ................................................................................................................31  
10.2. Appendix 2: Clinical Laboratory Tests ...........................................................................32  
10.2.1. Laboratory Samples to be Obtained  at the Time of a Systemic 
Hypersensitivity Event ....................................................................................................32  
10.3. Appendix 3: Adverse Events and Serious Adverse Events: Definitions and Procedures fo r Recording, Evaluating, Follow-
up, and Reporting ............................................................................................................34
 
10.4. Appendix 4: Contraceptive and Barrier Guidance ..........................................................35  
10.4.1. Definitions.......................................................................................................................35  
10.4.2. Contraception Guidance ..................................................................................................36  
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments ................................................................................................................... .[ADDRESS_580847] 2022 GMT
CCI
CCI
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
6 10.6. Appendix 9: Provisions for Ch anges in Study Conduct During 
Exceptional Circumstances .............................................................................................39  
10.7. Appendix 10: Abbreviations and Definitions .................................................................[ADDRESS_580848] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
7 1. Protocol Summary
1.1. Synopsis
Protocol Title:  
Randomized, Placebo-Controlled, Phase 2 Clin ical Trial to Evaluate LY3857210 for the 
Treatment of Chronic Low Back Pain Brief Title:  Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low 
Back Pain  
Regulatory Agency Identifier Numbers:   
LY3857210 IND: 156411 
Master Protocol IND: 144915 
Rationale: 
The purpose of this study is to test whether LY3857210 is efficacious in decreasing chronic low 
back pain (CLBP). LY3857210 is a small molecule receptor antagonist  of the P2X7 receptor, an 
adenosine triphosphate ligand-gated ion channel known to be involved in neuroinflammation and 
pain.  Data will be collected to asse ss the safety and tolerability of LY3857210 in this study population. 
The pharmacokinetics of LY3857210 will also be expl ored. The totality of data from this proof-
of-concept study will assess the benefits and risks associated with LY3857210 and inform 
decisions for the clinic al development of LY3857210. 
Objectives, Endpoints, and Estimands: The primary and secondary objectives and endpoint s are stated in the Master Protocol H0P-MC-
CPMP (CPMP) and the CLBP disease-state addendum (DSA; H0P-MC-CPMP[2]).  Overall Design: 
This is a 10-week, Phase 2, randomized, doubl e-blind, placebo-controlled study that will 
compare LY3857210 versus placebo in participants with CLBP.  
Study Population: 
In addition to inclusion and exclusion criteria described in Master Protocol CPMP and DSA 
CPMP(2), individuals may not take part in the study if they have 

an eGFR of less th an 30 mL/min/1.73 m
2, and

Approved on [ADDRESS_580849] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
8 Number of Participants: 
Up to approximately 125 participants will be ran domly assigned to study intervention with the 
assumption that 20% of the participants will drop out prior to the end of the double-blind 
treatment period. 
Intervention Groups and Duration: 
This double-blind study includes an 8-week treatme nt period with a 2-week  follow-up visit off 
treatment. 
Intervention Name [CONTACT_36940]3857210 Placebo
Dosage Level(s) 45 m g daily Not applicable 
Route of Administration 
and Duration PO PO
Abbreviation: PO = by [CONTACT_1966]. 
Ethical Considerations of Benefit/Risk: 
Taking into account the measures ta ken to minimize risk to partic ipants participating in this 
study, the potential risks identified in a ssociation with LY3857210 are justified by [CONTACT_454465] a fforded to participants with CLBP. 
Data Monitoring Committee: Yes Safety reviews are covered by [CONTACT_454466] (CPMP). 
Approved on [ADDRESS_580850] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
9 1.2. Schema 
Abbreviations: PDEP = preliminary data entry period; V = visit. 
a  Medication washout and PDEP begins. 
b  Randomization to either LY3857210 or placebo.  
Approved on [ADDRESS_580851] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
10 1.3. Schedule of Activities (SoA) 
This SoA shows visits and procedures uni que to the intervention-specific appendix (ISA) H0P-MC-BP05 for LY3857210. Please refer  
to the Master Protocol CPMP and the CLBP DSA CPMP(2) SoAs for additional information.  
Screening Randomizati
on to ISA Double-Blind Treatment F/U Notes 
V1 V2 V3 V4 V5 V6 V7 ED V801 
Study Week Up to -[ADDRESS_580852]
participants0 2 4 6 8 +2
Visit Window (days) ±3 ±[ADDRESS_580853], mammary gland in 
males, and lymph nodes should also be 
performed at V5 and V7. 
Neurological assessmen
t X X X X X X X See Section 8.2.1  
Prespecified CLBP 
medical histor y X   Includes diagnosis and symptom onset date. 
Vital signs X X X X X X X At V3, take vitals before dosing. 
Vitals include pulse rate, respi[INVESTIGATOR_697], blood pressure, and temp erature, taken with 
participant in a sittin g position. 
Concomitant medication X See footnote a. 
AE X See footnote a. 
ECG (single)  X  X X X 
Approved on [ADDRESS_580854] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
11 Screening Randomizati
on to ISA Double-Blind Treatment F/U Notes 
V1 V2 V3 V4 V5 V6 V7 ED V801 
Study Week Up to -[ADDRESS_580855]
participants0 2 4 6 8 +2
Visit Window (days) ±3 ±3 
Placebo response video 
trainin g (participant) X  Should view at the beginning of V2. 
Study intervention 
administration X X X X See Section 6.1. Instruct participant to NOT 
take stud y intervention on the da y of V7. 
Dispense Study 
intervention to 
participan t X X X X 
Participant returns unused study intervention X X X X X  Participant to bring study intervention to every visit. 
Intervention 
compliance X X X X X 
Scales, Questionnaires, and Outcome Measures 
C-SSRS Since Last
VisitX See footnote a. 
Self-Harm Supplement 
form X See footnote a. 
Self-Harm Follow-Up 
form X See footnote a. 
Complete [ADDRESS_580856] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
12 Screening Randomizati
on to ISA Double-Blind Treatment F/U Notes 
V1 V2 V3 V4 V5 V6 V7 ED V801 
Study Week Up to -[ADDRESS_580857]
participants0 2 4 6 8 +2
Visit Window (days) ±3 ±[ADDRESS_580858] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
13 Screening Randomizati
on to ISA Double-Blind Treatment F/U Notes 
V1 V2 V3 V4 V5 V6 V7 ED V801 
Study Week Up to -[ADDRESS_580859]
participants0 2 4 6 8 +2
Visit Window (days) ±3 ±3 
Abbreviations: AE = adverse event; ; ECG = electrocardiogram; ED = early discontinuation; F/U = follow-up; HbA1c = hemoglobin 
A1c; ISA = intervention-specific appendix; MoO = Manual of Oper ations; NRS = numeric rating scale; PGI = patient’s global impre ssion of change; PK = 
pharmacokinetic; V = visit; WOCBP = women of childbearing potential.  
a Collect in addition to schedule described in the Master Protocol CPMP. 
Approved on [ADDRESS_580860] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
14 2. Introduction
This ISA H0P-MC-BP05 (BP05) is an appendix to the Master Protocol H0P-MC-CPMP (CPMP) 
and contains unique study elements specific for LY3857210. The master pr otocol contains the 
overarching study elements that govern the CLBP DSA CPMP(2) and this ISA BP05.  
2.1. Study Rationale 
The purpose of this study is to test whethe r LY3857210 is efficacious in relieving CLBP. Data 
will be collected to assess th e safety and tolerability of LY3857210 in this study population. The 
PK of LY3857210 will also be explored. The tota lity of data from this proof-of-concept study 
will assess the benefits and risks associated  with LY3857210 and inform decisions for the 
clinical devel opment of LY3857210. 
2.2. Background 
P2X7 is an adenosine triphosphate (ATP) ligand-ga ted ion channel that when activated results in 
Ca2+ influx, and cellular activation (for example, caspase 1). For a recent review article, see 
Zhang et al. 2020. Stimulation of P2X7 plays a key ro le in the cross talk of the glial cells and 
neurons at an over-active synapse and in neur oinflammatory conditions  (Currò et al. 2020). 
Thus, inhibition of the P2X7 receptor found on g lial cells in the brain and spi[INVESTIGATOR_454462].  
LY3857210 is an orally admin istered small-molecule receptor antagonist of the P2X7 receptor.  
2.3. Benefit/Risk Assessment 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of LY3857210 may be found in the IB.   
2.3.1. Risk Assessment 
Study intervention 
Approved on [ADDRESS_580861] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
15 Toxicology Studies and NOAEL Exposure 
Based on the observed convulsion in the 3-month dog toxicology study (reported in 1 dog) as 
well as convulsion noted in the rat in vivo micronucleus study (reported in 1 rat), a 10-fold 
exposure multiple based on the observed AUC and C max associated with the NOEL for 
convulsions in dog (the most sensitive species) w ill be maintained in this 
In addition, neurological examination will be conducted at regular intervals during the study 
period and AEs related to CNS signs and symptoms will be collected during the study. 
Participants with a history of seiz ures will be excluded from the study.  
Potential drug-drug interactions 
Clinical drug-drug interaction studies ha ve not been conducted with LY3857210. Based on 
current in vitro data, LY3857210 is a potential  inducer of CYP3A4, CYP1A2, CYP2B6, and 
CYP2C8. To mitigate ris k, participants taking sensitive substrates with a narrow therapeutic 
index are excluded. See Section 5.2 for exclusion criteria and refe r to IB for more information. 
Information on AEs expected to be related to  the study intervention may be found in the IB. 
Information on SAEs that are expected in the study population independent  of drug exposure will 
be assessed by [CONTACT_104222] a ggregate, periodically during the course of the study, and may be 
found in the IB. 
2.3.2. Benefit Assessment 
Potential benefits for the study participants include  
information obtained from study-re lated medical procedures
ophysical examinations
olaboratory tests, and
oECGs
detailed evaluations of low back pain
olower back examination, and
olumbar X-rays, and
questionnaires that may improve particip ants understanding th eir own condition.
As part of Study CPMP, participan ts to this ISA will report their experience using standard tools 
that may contribute to the assessment of novel treatments for CLBP. In addition, data collected 
from this study may also improve  our understanding of CLBP pat hogenesis. Both of which may 
lead to the development of new treatment with improved safety and efficacy  profile compared to 
standard of care.  2.3.3. Overall Benefit Risk Conclusion 
Taking into account the measures ta ken to minimize risk to partic ipants participating in this 
study, the potential risks identified in a ssociation with LY3857210 are justified by [CONTACT_454465] a fforded to participants with CLBP. 
Approved on [ADDRESS_580862] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
16 3. Objectives, Endpoints, and Estimands
The Master Protocol CPMP and CLBP DS A CPMP(2) include objectives and endpoints 
applicable for this study. This table descri bes objectives and e ndpoints specific for LY3857210. 
Approved on [ADDRESS_580863] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
17 4. Study Design
4.1. Overall Design
The Master Protocol CPMP de scribes the overall study design and study design rationale. This 
section describes visits and overall procedures  unique to ISA BP05 for LY3857210 in addition to 
the procedures outlined in CPMP and CPMP(2).  
Double-blind treatment period (Visits 3 through 7) 
Each visit is an outpatient visit. At Visit 3 
participants are randomly assi gned to LY3857210 or placebo
the site completes the BP05 baseline proce dures and sample colle ction prior to study
intervention
the site collects participants’ vitals predose
participants receive thei r oral study intervention
the site completes PK sample collection, and
the site instructs participants to continue with study restrictions and NRS diary entries
before their visit discharge.
At Visits 4 through 7 
the site reviews available safety data and sample collection
participants continue oral st udy intervention (not applicable for V7) and bring all study
intervention bottles to each visit
the site completes all sample collection and safety monitoring noted in the SoAs, and
the site instructs participants to continue with study restrictions, including not using
medications for chronic pain, NRS diary entries and wearing of  before their
visit discharge.
Double-blind post-treatment fo llow-up period (Visit 801) 
Participants must complete [ADDRESS_580864] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580865] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
19 5. Study Population
The Master Protocol CPMP and CLBP DSA CPMP(2) provide eligib ility criteria that must be 
followed for this study. LY3857210-specific inclus ion and exclusion crite ria are listed here. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Sex and contraceptive/barrier requirements 
[2075]  Males and females may participate in this trial.  
No male contraception is required excep t in compliance with specific local 
government study requirements. 
WOCBP and WNOCBP may participate in this trial. See Section 10.4 for definitions 
and additional requirements  related to contraception. 
Contraceptive use by [CONTACT_454467] t hose participating in clinical studies.  
5.2. Exclusion Criteria  
Participants are excluded from the study if  any of the following criteria apply: 
[2077]  Have an eGFR of <30 mL/min/1.73 m 2, based on the Chronic Kidney Disease 
Epi[INVESTIGATOR_10444] (CKD-EPI) formula at Visit 1 or Visit 2. 
[2078]  Have known allergies to LY3857210, related compounds or  any components of the 
formulation, or histor y of significant atopy.  
[2079]  Women who are pregnant or breastfeeding. 
Approved on [ADDRESS_580866] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580867] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
21 6. Study Intervention(s) and Concomitant Therapy
6.1. Study Intervention(s) Administered
This table lists the interventions  used in this clinical study. 
Intervention Name  [CONTACT_36940]3857210 Placebo
Dosage Level(s) 45 mg daily N/A 
Route of Administration PO PO
Abbreviations: N/A = not applicable; PO = by [CONTACT_1966]. 
Packaging and labeling 
Study interventions will be supplie d by [CONTACT_454468]. Study interventions will be labeled as ap propriate for country 
requirements. 
6.2. Preparation, Handling, Storage, and Accountability 
Preparation, handling, storage, a nd accountability are described in  the Master Protocol CPMP. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
Randomization and blinding are describe d in the Master Protocol CPMP. 
6.3.1. Stratification 
There are no additional stratific ation factors for this study. 
6.4. Study Intervention Compliance 
When participants self-admin ister study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Co mpliance will be assessed by [CONTACT_454469], and documented in the source documents and CRF. A record of the 
number of study intervention capsules dispensed to and taken by [CONTACT_21444]. Intervention start and 
stop dates, will also be recorded in the CRF. 
6.5. Dose Modification 
Dose modification is not permitted. 
6.6. Continued Access to Study Interventi on after the End of the Study 
Not applicable. 
Approved on [ADDRESS_580868] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580869] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
23 7. Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
The Master Protocol CPMP and DSA CPMP(2 ) provide the reasons and procedures for 
discontinuation of intervention a nd participant discontinuation that  must be followed for this 
study.  
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_454463] (see Section 8.2.5. 
of the Master Protocol CPMP) if [ADDRESS_580870] >8x ULN 
ALT or AST >5x ULN for more than [ADDRESS_580871] >3x ULN and either TBL >2x ULN or INR >1 .5 For participants w ith Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be used for drug interruption decisions rather than TBL>2x ULN. 
ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
ALP >3x ULN, when the source of increased ALP is the live r
ALP >2.5x ULN and TBL > 2x ULN For pa rticipants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL then doubling of direct bilirubin should be used for drug interruption decisions rather 
than TBL>2x ULN. 
ALP >2.5x ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%) 
Source: FDA 2009 and other consensus guidelines, with minor modifications. 
Abbreviations: ALP = alkaline phosphat ase; ALT = alanine aminotransferase ; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = tota l bilirubin level; ULN = upper limit of normal. 
Resuming study intervention after elevated liver tests 
Resumption of the study intervention can be considered only in consultation with the 
Lilly-designated medical monitor and only if the li ver test results return to baseline and if a 
self-limited, non-drug etiology is identified. Otherwise, the study in tervention should be 
discontinued. 
Approved on [ADDRESS_580872] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
24 7.1.2. Hypersensitivity  
If the investigator determines that a systemic hypersensitivity reaction has occurred related to 
study intervention administration, the participant may be permanently discontinued from the 
study intervention, and the sponsor’s designated medical monitor should be notified. If the 
investigator is uncertain about  whether a systemic hypersensitivity reaction has occurred and 
whether discontinuation of study intervention is warranted, the investigator may consult the 
sponsor. 
For laboratory samples to be obt ained at the time of a syste mic hypersensitivity event, see 
Section 10.2.1.  
7.2. Participant Discontinuation/Withdrawal from the Study 
See the Master Protocol CPMP. 
7.3. Lost to Follow-Up 
See the Master Protocol CPMP. 
Approved on [ADDRESS_580873] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580874] er Protocol CPMP, CLBP DSA 
CPMP(2), and ISA BP05 SoAs.  
LY3857210-specific assessments and procedures are described here. 
8.1. Efficacy Assessments 
Planned time points for all efficacy a ssessments are provided in the SoAs. 
See the Master Protocol CPMP and DSA CP MP(2) for additional information on efficacy 
assessments. 
8.2. Safety Assessments 
Planned time points for all efficacy a ssessments are provided in the SoAs. 
See the Master Protocol CPMP and DSA CP MP(2) for additional information on safety 
assessments. Additional Study BP05-specific assessment information is  provided below. 
8.2.1. Physical Examinations 
Complete physical examinati on, including targeted examination specified below, should be 
performed at V3 and Visit [ADDRESS_580875], mammary gland in males, and lymph nodes will also be pe rformed at Visits V5 and V7 as 
described in the SoA. Any clinically significan t abnormal physical examin ation findings will be 
reported as AEs. 
In addition, a directed neurologi cal assessment will be performed by [CONTACT_454470]. If abnorma lities are noted at thes e time points, additional 
examinations should be performed as clinically necessary. The examiner should be familiar with 
the participant’s baseline examination.  
Elements of the neurological a ssessment include inspection for tremor, extraocular movements, 
brachial and patellar deep tendon reflexes , finger-nose pointing, and Romberg sign.  
8.2.2. Electrocardiograms 
Single 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, RR, QRS, QT, and QTcF 
CCI
Approved on [ADDRESS_580876] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
26 intervals. Refer to Section 7.1. of  the Master Protocol CPMP fo r QTcF withdrawal criteria and 
any additional QTcF readi ngs that may be necessary. 
Additional details related to ECG are provided in the Master Protocol CPMP. 
8.2.3. Clinical Safety Laboratory Tests 
See BP05 Section 10.2 (Appendix 2) for the list of clinical laboratory tests to be performed and 
to the SoA for the timing a nd frequency for ISA BP05.  
Additional details are provided in  the Master Protocol CPMP. 
8.3. Adverse Events, Serious Adverse Events, and Product Complaints 
The definitions of AEs, SAEs, and PCs can be  found in Appendix 3 of the Master Protocol 
CPMP. 
See the Master Protocol CPMP Section 8.3 for additional details. 
8.3.1. Pregnancy 
Collection of pregnancy information 
Male participants with partners who become pregnant 
●The investigator will attempt to coll ect pregnancy information on any male
participant’s female partne r who becomes pregnant while the male participant is
in this study. This applies only to male participants  who receive study
intervention.
●After learning of a pregnancy in the fema le partner of a stud y participant, the
investigator
owill obtain a consent to release informat ion from the pregnant female partner
directly, and
owithin [ADDRESS_580877] pregnancy information
on the appropriate form and s ubmit it to the sponsor.
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age,  fetal status (prese nce or absence of 
anomalies) or indicatio n for the procedure. 
Female participants who become pregnant 
●The investigator will coll ect pregnancy information on any female participant
who becomes pregnant while participating in this st udy. The initial information
will be recorded on the appr opriate form and submitted to the sponsor within 24
hours of learning of a pa rticipant's pregnancy.
Approved on [ADDRESS_580878] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
27 ●The participant will be followed to determine the outcome of the pregnancy. The
investigator will collect follow-up information on the participant and the neonate
and the information will be forwarded to  the sponsor. Generally, follow-up will
not be required for longer than 6 to 8 weeks beyond the estim ated delivery date.
Any termination of pregnancy will be reported, regardless of gestational age,  fetal
status (presence or absence of anoma lies) or indication for the procedure.
●While pregnancy itself is not considered  to be an AE or SAE, any pregnancy
complication or elective termination of a pregnancy for medical reasons will bereported as an AE or SAE.
●A spontaneous abortion, occurring at <20 weeks gestational ag e, or still birth,
occurring at ≥20 weeks gestational age, is always  considered to be an SAE and
will be reported as such.
●Any post-study pregnancy related SAE considered reasonably related to the study
intervention by [CONTACT_454471]  8.3.1. While the investigator  is not obligated to
actively seek this information in former study participants, they may learn of an
SAE through spontaneous reporting.
●Any female participant w ho becomes pregnant while participating in the study
will discontinue study intervention and con tinue directly to the follow-up phase.
The follow-up on the pregnancy outcome should continue independent of
intervention or st udy discontinuation.
8.3.2. Hypersensitivity Reactions 
Many drugs, including oral agents and biologic agents, carry the risk  of systemic hypersensitivity 
reactions. If such a reaction occu rs, additional data should be provided to the sponsor in the 
designated CRFs. 
Sites should have appropriat ely trained medical staff and appropriate medical equipment 
available when study participan ts are receiving study interven tion. It is recommended that 
participants who experience a systemic hypersen sitivity reaction be treated per national and 
international guidelines. 
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as described in Section 10.2.1. Laboratory results are provi ded to the sponsor via the 
central laboratory. 
8.3.3. Adverse Events of Special Interest  
Convulsion is an AE of special interest for LY3857210 and will be subject to enhanced 
surveillance activities. Additionally, convulsion will be analyzed for presentation in the Clinical Study Report in accordance with the SAP. 
If a seizure or convulsion is reported, then c ontact the medical monito r as soon as possible. 
Additional evaluation or follow-up may be requested.  
Approved on [ADDRESS_580879] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
28 8.4. Pharmacokinetics 
Blood samples will be collected for measuremen t of plasma concentrations of LY3857210 as 
specified in the SoA.  
A maximum of 3 samples may be collected at  additional time points during the study if 
warranted and agreed upon between  the investigator and the spons or. The timing of PK samples 
may be altered during the course of the study based on newly availabl e data to ensure appropriate 
data collection.  Instructions for the collection and handling of  PK samples will be provided by [CONTACT_456]. 
The date and time (24-hour cloc k time) will be recorded for  
LY3857210 administration prior to the PK sample collection, and
PK sample collection.
PK samples may also be used to evaluate safety or efficacy meas ures related to concerns arising 
during or after the study.  
8.5. Pharmacodynamics 
Pharmacodynamic assessments will not be evaluated in this study. 
8.6. Genetics 
See the Master Protocol CPMP for de tails related to genetic sampling. 
Approved on [ADDRESS_580880] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
29 9. Statistical Considerations
The Master Protocol CPMP a nd CLBP DSA CPMP(2) provide statistical considerations. 
LY3857210-specific consideratio ns are described here. 
9.1. Statistical Hypotheses 
The Master Protocol CPMP describes the prima ry hypothesis. 
9.2. Analyses Sets 
The populations are defined in the Master Protocol CPMP. 
The PK population includes all randomly as signed participants who received a dose of 
LY3857210 and have at least [ADDRESS_580881] in formation will be specified in the ISA SAP. 
Secondary and tertiary/explorator y endpoints and analyses are desc ribed in the Master Protocol 
CPMP and CLBP DSA CPMP(2).  Handling of missing, unused, and sp urious data is addressed pr ospectively in the overall 
statistical methods described in the protocol and in the SAP, wh ere appropriate. Adjustments to 
the planned analyses are described in the final CSR. 
9.3.2. Tertiary Analysis 
Exploratory analyses may be described in the ISA SAP. 
Approved on [ADDRESS_580882] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580883] been described in the Master Protocol CPMP. Additional ISA-specific 
safety analyses may be de scribed in the ISA SAP.  
9.3.4. Exploratory Pharmacokinetic Analyses 
Plasma concentrations for LY 3857210 will be reported graphica lly and descriptively. Model-
based PK and exposure-response relationships for various efficacy and safety measures may be conducted. 
9.4. Interim Analysis  
An interim analysis may be c onducted for internal decision ma king. The potential reasons for 
interim analyses could include fu tility analyses, early efficacy analyses, safety analyses, PK 
analyses or other analyses need ed for key business decisions a nd planning. Unblinding details 
would be specified in the unblinding plan se ction of the SAP or in a separate unblinding 
document. The SAP will describe any interim anal yses in greater detail should they occur.  
9.5. Sample Size Determination 
Up to approximately 125 participants will be randomly assigned to LY3857210 and placebo. It is 
expected that approximately 80% of participan ts will complete the doubl e-blind treatment period 
of the study. 
 If there is no treatment 
difference between placebo and LY3857210, the probabi lity of meeting the primary objective 
specified above (that is , false positive) is ≤0.05.  
Approved on [ADDRESS_580884] 2022 GMT
CCI
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
31 10. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
See the Master Protocol CPMP  for regulatory, ethical, and st udy oversight considerations. 
Approved on [ADDRESS_580885] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
32 10.2. Appendix 2: Clinical Laboratory Tests 
The Master Protocol CPMP describes tests that may be performed at additional times noted in 
the SoA for this ISA. This table de scribes tests unique for ISA BP05.  
Other Tests Assa yed by [CONTACT_11007]-desi gnated laborator y 
LY3857210 concentration Results will not be provided to the investi gative sites 
10.2.1. Laboratory Samples to be Obtained at th e Time of a Systemic Hypersensitivity 
Event 
Purpose of collecting samples after a systemic hypersensitivity event 
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the labor atory tests results from th ese samples to characterize 
hypersensitivity events across the clinical development program. 
When to collect samples after a syst emic hypersensitivity event occurs 
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assu ming the participant ha s been stabilized. 
Obtain follow-up pre-dose samples at the next re gularly scheduled labora tory sample collection 
(ideally prior to the next dose after the event)  to assess post-event return-to-baseline values. 
Timing Laboratory Test a 
Collect from 30 minutes to 4 hours after the start of 
the event. 
●Note: The optimal collection time is from 1 to  2
hours after the start of event. total tr yptase 
complements (C3, C3a, and C5a) 
cytokine panel (IL-6, IL ‐1β, IL‐10 or any cytokine 
panel that includes these 3 c ytokines)  
Abbreviation: IL = interleukin. 
a All samples for hypersensitivity testing will be assaye d by [CONTACT_11007]-designated laboratory. Results will not be 
provided to the study site. If samples are not collected or  are collected outside the specified time period, this will 
not be considered a protocol deviation. 
What information to record  
Record the date and time when the samples are collected. 
Approved on [ADDRESS_580886] 2022 GMT
CCI
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580887] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
34 10.3. Appendix 3: Adverse Events and S erious Adverse Events: Definitions 
and Procedures for Recording,  Evaluating, Follow-up, and 
Reporting 
See the Master Protocol Appendix [ADDRESS_580888] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
35 10.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Definitions 
Word/Phrase Definition 
Women of 
childbearing 
potential (WOCBP) Adult females are considered WOCBP unless they are WNOCBP. 
Women not of childbearing potential 
(WNOCBP) Females are considered WNOCBP if they 
have a congenital anomaly such  as Müllerian agenesis
are infertile due to surg ical sterilization, or
are postmenopausal.
Examples of surgical sterilization include total hysterectomy, bilateral salpi[INVESTIGATOR_8936]-oophorectomy, b ilateral salpi[INVESTIGATOR_1656], or bilateral oophorectomy. 
Postmenopausal 
state The postmenopausal state is defined as a woman: 
at any age at least 6 weeks pos t-surgical bila teral oophorectomy
with or without hysterectomy, co nfirmed by [CONTACT_31083]; or
aged at least [ADDRESS_580889]
12 consecutive months without an  alternative medical cause, AND
with a follicle-stimulating hormone >40 mIU/mL; or
[ADDRESS_580890] 12
months of spontane ous amenorrhea, or
aged at least 55 years with a diagnosis of menopause prior to
starting hormone re placement therapy.
a Women should not be taking medications  during amenorrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti-estrogens, 
selective estrogen receptor modulator s (SERMs), or chemotherapy that 
could induce transient amenorrhea. 
Approved on [ADDRESS_580891] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
36 10.4.2. Contraception Guidance 
WOCBP who are completely abstinent as their pref erred and usual lifestyle, or in a same-sex 
relationship as their prefe rred and usual lifestyle: 
Must… Must not… 
agree to either 
remain abstinent or 
stay in a same-sex 
relationship without sexual relationships 
with males use periodic abstinence methods
ocalendar
oovulation
osymptothermal, or
opost-ovulation
declare abstinence just for th e duration of a trial, or
use the withdrawal metho
d
WOCBP who are NOT completely abstinent as thei r preferred and usual lifestyle, or NOT in a 
same-sex relationship as th eir preferred and usual lifes tyle, must do the following: 
Topic Condition 
Pregnancy testing Have a negative serum test  result at screeni ng followed by a negative 
urine result within [ADDRESS_580892] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
37 Examples of different forms of contraception: 
Methods Examples 
Highly effective 
contraception (less than 
1% failure rate) female sterilization
combination oral contraceptive pi[INVESTIGATOR_4382]
progestin-only contraceptive pi[INVESTIGATOR_4382] (mini-pi[INVESTIGATOR_4382])
implanted contraceptives
injectable contraceptives
contraceptive patch (only women <198 pounds or 90 kg)
total abstinence
vasectomy (if only sexual partner)
fallopi[INVESTIGATOR_31077] (if confirmed by [CONTACT_31084][INVESTIGATOR_8913])
combined contraceptiv e vaginal ring, or
intrauterine devices
Effective contraception male or female condoms  with spermicide
diaphragms with spermici de or cervical sponges
barrier method with us e of a spermicide
ocondom with spermicide
odiaphragm with spermicide, or
ofemale condom with spermicide
Ineffective forms of contraception whether used alone or in any 
combination spermicide alone
periodic abstinence
fertility awareness (calenda r method, temperature method,
cervical mucus, or symptothermal)
withdrawal
postcoital douche, or
lactational amenorrhe
a
Approved on [ADDRESS_580893] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
38 10.5. Appendix 5: Liver Safety: Su ggested Actions and Follow-up 
Assessments  
See the Master Protocol CPMP Appendix 6 for liver safety: suggested actions and follow up 
assessments. 
Approved on [ADDRESS_580894] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
39 10.6. Appendix 9: Provisions for Changes in Study Conduct During 
Exceptional Circumstances 
Implementation of this appendix 
The changes to procedures described in this appendix are temporary m easures intended to be 
used only during specific time pe riods as directed by [CONTACT_454472]. 
Exceptional circumstances 
Exceptional circumstances are rare  events that may cause disrup tions to the conduct of the study. 
Examples include pandemics or natu ral disasters. These disruptions  may limit the ability of the 
investigators, participants, or both to attend on-site visits or to conduct planned study procedures. 
Implementing changes under exceptional circumstances 
In an exceptional circumstance,  after receiving the sponsor’s  written approval, sites may 
implement changes if permi tted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for  example, upon implementation a nd suspension of changes). All 
approvals and notificatio ns must be retained  in the study records.  
If the sponsor grants written approval for change s in study conduct, the sponsor will also provide 
additional written guidance, if needed. 
Considerations for making a change 
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considera tions for making a change are compliance with Good Clinical 
Practice, enabling participants to continue safely in the study and maintain ing the integrity of the 
study.  
Informed consent 
Additional consent from the participant will be obtained, if required, for: 
participation in remote visits, as defined in Section “Remote Visits”
dispensation of additional st udy intervention during an extended treatment period
alternate delivery of study intervention and ancillary supplies, and
provision of their personal or  medical information required prior to implementation of
these activities.
Changes in study conduct durin g exceptional circumstances 
Changes in study conduct not described in this appe ndix, or not consistent with applicable local 
regulations, are not allowed. 
Approved on [ADDRESS_580895] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580896] will not be considered pr otocol deviations. 
Remote visits 
Telemedicine:  Telephone or technology-assisted virtua l visits, or both, are acceptable to 
complete appropriate assessments.  
Mobile healthcare:  Healthcare visits may be perfor med by a mobile healthcare provider 
at locations other than the study site when part icipants cannot travel to the site due to an 
exceptional circumstance if written approval is provided by [CONTACT_456].  
Procedures performed at such visits include, but are not li mited to, collection of blood 
samples, symptom directed physical exa minations, ECGs, vital signs, intervention 
accountability and compliance, AE collection, and collection of h ealth information. 
Other alternative locations: Laboratory draws may be done at an alternate location in 
exceptional circumstances.  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing becaus e of missed in-person site visits. 
Regardless of the type of remote visits impleme nted, the protocol requ irements regarding the 
reporting of AEs, SAEs, a nd PCs remain unchanged.  
Every effort should be made to enable particip ants to return to on-site visits as soon as 
reasonably possible, while ensuring the safety of  both the participants and the site staff. 
Local laboratory testing option 
Local laboratory testing may be  conducted in lieu of central  laboratory testing. The local 
laboratory must be qualifie d in accordance with app licable local regulations. 
Study intervention and ancillary supplies (including participant diaries) When a participant is unable to go to the site  to receive study supplies during normal on-site 
visits, the site should work with the sponsor to  determine appropriate ac tions. These actions may 
include:  
asking the participant to go to the site and receive study supp lies from site staff
without completion of a full study visit
asking the participant’s desi gnee to go to the site a nd receive study supplies on a
participant’s behalf, and
arranging delivery of study supplies.
These requirements must be met before action is taken: 
Alternate delivery of study intervention s hould be performed in a manner that does
not compromise treatment blinding and ensures product integrity. The existing
protocol requirements for product acc ountability remain unchanged, including
verification of participant’ s receipt of study supplies.
Approved on [ADDRESS_580897] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
41 When delivering supplies to a location other than the study site (for example,
participant’s home), the inves tigator, sponsor, or both shoul d ensure oversight of the
shippi[INVESTIGATOR_51961] (that is, storage
conditions maintained and inta ct packaging upon receipt).
Instructions may be provided  to the participant or desi gnee on the final disposition of
any unused or comple ted study supplies.
Adjustments to visit windows  
Whenever possible and safe to do so, as determin ed by [CONTACT_093]’s discretion, participants 
should complete the usual Schedul e of Activities as de scribed in the Master  Protocol CPMP , 
CPMP(2) DSA, and BP05 ISA. To maximize the possi bility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon furt her guidance from the sponsor. 
This minimizes missing data and preser ves the intended cond uct of the study.  
For participants whose visits have extended wi ndows, additional study in tervention may need to 
be provided to avoid interruption and main tain overall integr ity of the study.  
Documentation Sites will identify and document the details of  how participants, visit types, and conducted 
activities were affected by [CONTACT_52022]. Dispen sing/shipment records of study 
intervention and relevant communi cations, including delegation, s hould be filed with site study 
records. 
Source documents generated at a location other than the study s ite should be part of the 
investigator’s source documentation and should be transferred to the site in a secure and timely 
manner.  
Approved on [ADDRESS_580898] 2022 GMT
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
42 10.7. Appendix 10: Abbreviations and Definitions 
Term Definition
AE adverse event  
ALT alanine aminotransferase 
AUC area under the curve 
AST aspartate aminotransferase 
CLBP chronic low back pain 
CNS central nervous system 
CPMP chronic pain master protocol 
CRF case report form; a printed, optical, or electr onic document designed to record all of the 
protocol-required information to be reported  to the sponsor for each trial participant. 
DSA disease-state appendix 
ECG electrocardiogram 
ED early discontinuation 
eGFR estimated glomerular filtration rate 
IB Investigator’s Brochure 
ISA intervention-specific appendix 
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked. 
MAD multiple-ascending dose 
MoO Manual of Operations 
NOAEL No observed adverse effect level 
NOEL no observable effect level 
NRS numeric rating scale 
participant Equivalent to CDISC term “subject”: an indivi dual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_454464] a control 
PC product complaint 
PK pharmacokinetics 
Approved on [ADDRESS_580899] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580900] 2022 GMT
CCI
CONFIDENTIAL Protocol number H0P-MC-BP05 (a) 
[ADDRESS_580901] on the 
activation of presynaptic AMPA receptors in ra t trigeminal caudal nucleus glutamatergic nerve 
terminals. J. Headache Pain . 2020;21(1):83. https://doi.org/10.1016/j.pain.2005.01.002 
Zhang WJ, Zhu ZM, Liu ZX. The role and pharmacological properties of the P2X7 receptor in 
neuropathic pain. Brain Res Bull . 2020;155:19-28. 
https://doi.org/10.1016/j.brainresbull.2019.11.[ADDRESS_580902] 2022 GMT